跳至主要内容
临床试验/NCT06809803
NCT06809803招募中2 期

Safety, Convenience, and Tolerability of a Nightly Single Oral Dose of Extended-release Sodium Oxybate in Children

Stanford University1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年10月27日最近更新:
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
36
试验地点
1
主要终点
Participant preference for selecting the extended vs non-extended release oxybates

研究概览

简要总结

The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
7 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Participants must be under the care of a doctor at the Stanford Sleep Clinic.
  • Participants must have a documented diagnosis of narcolepsy type 1 shown by sleepiness and either: a spinal fluid marker for narcolepsy (hypocretin-1) at a specific level, or a history of sudden loss of muscle control (cataplexy), or a particular genetic marker for narcolepsy, or a sleep study showing a specific sleep pattern for narcolepsy.
  • Parent(s), or guardian(s) have signed a consent form and the child must agree to participate.
  • Participants are on a stable dose of medications

排除标准

  • Participants who have any of the following conditions will not be included in the study
  • Uncontrolled mental health problems
  • Uncontrolled sleep problems that lead to sleepiness.
  • Currently having thought about ending one's life or sadness or loss of interest
  • Currently having a problem with illegal drug use
  • Currently pregnant

研究组 & 干预措施

Extended-release sodium oxybate

Experimental

Participants in this arm will take extended-release sodium oxybate

干预措施: Extended-release sodium oxybate (Drug)

Extended-release sodium oxybate

Experimental

Participants in this arm will take extended-release sodium oxybate

干预措施: Non-extended-release oxybates (Drug)

Non-extended-release oxybates

Active Comparator

Participants in this arm will take non-extended-release sodium oxybate

干预措施: Extended-release sodium oxybate (Drug)

Non-extended-release oxybates

Active Comparator

Participants in this arm will take non-extended-release sodium oxybate

干预措施: Non-extended-release oxybates (Drug)

结局指标

主要结局

Participant preference for selecting the extended vs non-extended release oxybates

时间窗: Baseline, up to 8-12 weeks through study completion

Participants will be asked at the end of the study whether participants prefer extended-release sodium oxybate vs sodium oxybate vs calcium, magnesium, potassium and sodium oxybates

次要结局

  • Change in Epworth Sleepiness Scales for Children and Adolescents (ESS-CHAD) score(Baseline, up to 8-12 weeks through study completion)
  • Number of cataplexy attacks(Baseline, up to 8-12 weeks through study completion)
  • Change in Patient Global Impression of Change (PGIc) scale score(Baseline, up to 8-12 weeks through study completion)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Oliver Sum-Ping

Clinical Associate Professor in Psych/Sleep Medicine

Stanford University

研究点 (1)

Loading locations...

相似试验

Extended-release Sodium Oxybate in Children | 临床试验